Central Centrifugal Cicatricial Alopecia – CCCA
Central centrifugal cicatricial alopecia (CCCA) is a form of primary lymphocytic scarring (cicatricial) alopecia. It causes permanent hair loss that begins at the center of the scalp (the vertex or crown) and then slowly spreads outward in a centrifugal pattern. CCCA is most common in women of African descent, but it is being recognized increasingly in other ethnic groups as well.
CCCA results from several interacting factors: genetics, cellular stress, autoimmune inflammation, and mechanical or chemical triggers:
- Genetics and PADI3 mutations: Recent research has found mutations in the PADI3 gene (which encodes the enzyme peptidylarginine deiminase 3) in a large share of patients with CCCA. This enzyme modifies the proteins that build the hair shaft and the inner root sheath. When it is deficient or faulty, the hair shaft is weak and breaks easily, and inflammation is triggered inside the follicle cells.
- Endoplasmic reticulum stress (ER stress) and fibrosis: A buildup of abnormal proteins inside the follicle sets off an ER stress response that leads to programmed cell death (apoptosis) of follicular epithelial cells. This in turn activates fibroblasts to produce more collagen, so the follicle is replaced by firm scar tissue.
- Autoimmune lymphocyte attack on stem cells: As in other lymphocytic scarring alopecias, CD4+ and CD8+ T cells target the follicular bulge region. Once the hair follicle stem cells there are destroyed, the follicle can no longer regenerate.
- Mechanical and chemical triggers: Hair treatments involving tension or high heat (chemical relaxers, hot styling, very tight braids, heavy silicone- or mineral-oil-based pomades) act as triggers, worsening inflammation around follicles that are already genetically vulnerable.
At Haute-Derma, caring for patients with CCCA combines medical control of inflammation, changes to hair care habits, and newer anti-fibrotic therapies.
Clinical Features and Differential Diagnosis
CCCA is recognized by the pattern of hair loss and by signs of inflammation at its advancing edge:
- Centrifugal spread (centrifugal pattern): Hair loss starts quietly at the crown or the hair whorl. The bald patch slowly widens outward in a fairly symmetric circle or oval.
- Scarred, thinned scalp with no follicle openings: The center of the patch is smooth and shiny, the scalp is thin and slightly firm to the touch, and there is a complete loss of follicular openings (loss of follicular ostia).
- Uncomfortable symptoms: Patients often notice intense itching, prickling, mild burning, or a deep tight feeling along the expanding edge of the patch.
- Trichoscopy (magnified scalp examination) findings:
- White halo around the hair shaft (peripilar white halo): the most characteristic trichoscopic sign of CCCA, reflecting fibrosis around the follicle opening.
- Honeycomb pigment network (honeycomb hyperpigmentation): caused by melanin collecting in the scalp epidermis.
- Black dots, short broken hairs, and hairs clustered in tufts (tufted hair) at the advancing edge.
Haute-Derma's Approach to Diagnosis and Treatment
- Histologic diagnosis and early detection: Trichoscopy is used to pinpoint the edge of the patch where inflammation is still active. A 4 mm scalp punch biopsy is then taken from the border between scarred and healthy scalp:
- Histology findings: lymphocytic inflammation around the upper part of the follicle, loss of sebaceous glands, and, most tellingly, columns of scar tissue (fibrous tracts) where follicles used to be.
- Anti-inflammatory and anti-fibrotic medical treatment:
- Topical and intralesional corticosteroids (ILTAC): triamcinolone acetonide injected along the edge of the patch, combined with topical clobetasol propionate, to quickly calm the lymphocytic inflammation.
- Oral anti-inflammatory antibiotics (doxycycline / minocycline): given at anti-inflammatory doses for 3–6 months to ease itching and burning and reduce inflammatory cell infiltration.
- Metformin 10% cream (a new anti-fibrotic approach): one of the most recent advances. Topical metformin activates the AMPK signaling pathway, which helps reverse dermal fibrosis and encourages small blood vessels around the follicles to regenerate.
- Calcineurin inhibitors (tacrolimus 0.1%): a safe option for long-term maintenance on the crown.
- Changing hair care habits and cosmetic restoration:
- Stop all high-heat styling (hot combs, flat irons) and cut back on bleaching, dyeing, and harsh perming or relaxing chemicals.
- Choose natural hairstyles that put as little tension on the roots as possible.
- Once the disease has been in a completely inactive (burned-out) phase for at least 18–24 months, scalp micropigmentation (SMP) can be considered to camouflage the scarred patch on the crown.
How CCCA Compares With Other Common Causes of Crown Hair Loss
| CCCA | Male/Female Pattern Hair Loss (AGA/FPHL) | Lichen Planopilaris (LPP) |
|---|---|---|
| Scarring hair loss (follicle openings lost). | Non-scarring hair loss (follicles shrink). | Scarring hair loss (follicle openings lost). |
| Spreads outward from the center of the crown. | Diffuse thinning along the part or at the crown (follicle openings preserved). | Scattered patches on the crown and temples. |
| White halo around the hair shaft (peripilar white halo). | Hairs of varying thickness (miniaturization). | Scaly sleeves around the base of the hair shaft (perifollicular casts). |
| Gradual onset; forms a soft scarred patch in the center. | Slow, over many years; no scarring. | More acute, with marked burning pain and thick scale. |
